Canada: Protecting Pharmaceutical Tablets

Last Updated: May 28 2015
Article by John McKeown

A recent decision of the Federal Court refused to provide trademark protection for the colour and shape of the VIAGRA little blue pill.

The Trademark

On January 19, 2005, Pfizer Products Inc. (Pfizer) applied to register a trademark, for the VIAGRA TABLET DESIGN (the "Mark") based on its use in Canada since at least as early as March 1999 in association with a pharmaceutical preparation for the treatment of sexual dysfunction (the "Wares"). The drawings and description of the trademark are shown below:

Colour was claimed as a feature of the trademark. The trademark consisted of the colour blue as applied to the whole of the visible surface of the tablet shown in the drawings.

The Opposition

The Canadian Generic Pharmaceutical Association (CGPA) opposed the application and an oral hearing was held in May 2012.

The Trademark Opposition Board (the "Board") refused the application. The Board concluded that the Mark was not distinctive as required by the Trademarks Act. The Board said that the relevant test required that the Pfizer show that physicians, pharmacists and patients recognized the Mark as a trademark and not just as an ornamental or functional element of the product.

The Board considered the evidence regarding the marketing and sales of Viagra, as well as the evidence from physicians and pharmacists regarding patients' perceptions of the Mark. It was found that the evidence supported a finding that many patients had been exposed to Viagra advertising and that some patients referred to Viagra as the "little blue pill". The Mark had a reputation among at least some consumers. The Board concluded that the Mark was distinctive among patients because the evidence showed that patients associate the Mark with the Wares.

However, the Board concluded that Pfizer had not established that the Mark was distinctive among physicians and pharmacists. Pfizer failed to establish that a significant number of physicians and pharmacists relate the Mark to prescribing and dispensing of the Wares. The opposition succeeded because the Applicant had failed to establish distinctiveness in relation to patients and physicians and pharmacists.

The Appeal

Pfizer appealed this decision to the Federal Court. Pfizer filed additional evidence as it was entitled to. Pfizer argued that the Board erred in its application of the test for distinctiveness by requiring that distinctiveness be established among patients, physicians, and pharmacists. Pfizer said that establishing distinctiveness among patients should be sufficient. New evidence was also filed to attempt to establish distinctiveness among physicians and pharmacists.


The trial judge set out a useful summary of a number well established general principles relating to distinctiveness:

a) In order to establish the distinctiveness of the proposed Mark, the onus was on Pfizer to establish: (i) that the Mark and the Wares were associated; (ii) that Pfizer used the association between the Mark and the Wares; and (iii) that the association enabled Pfizer to distinguish its Wares from those of others;

b) A trademark indicates the source of a particular product so that consumers know what they are buying and from whom and only a distinctive mark will allow the consumer to identify the source of the product;

c) Distinctiveness is the quality that allows consumers to reference the trademark to distinguish the origin of a product and is the very essence and cardinal requirement of a trademark;

d) The critical question is what the trademark actually conveys to the consumer.

e) For the appearance of the product itself, in this case consisting of the blue, diamond-shaped pill, to be distinctive, the appearance must convey information concerning the source of the Wares.

After a lengthy review of the existing case law the judge agreed with Pfizer that establishing distinctiveness among patients should be sufficient. In considering the distinctiveness of the appearance of a pharmaceutical tablet, the Board or a court must look at whether the evidence establishes recognition, to "any significant degree," among patients or physicians and pharmacists as the "ordinary consumers" of the Mark.

The Trademark Act law applies to the pharmaceutical industry in the same way as it does to all other industries. Pfizer was required to adduce sufficient evidence to establish that, on a balance of probabilities, consumers associate the Mark with a single source of manufacture to a significant degree. The consumers of Viagra include physicians, pharmacists, and patients. If Pfizer demonstrated a significant degree of recognition among any of these consumers, Pfizer would establish that the Mark was distinctive.

The judge then concluded that the Board was wrong in law in failing to consider whether distinctiveness amongst patients satisfied the requirement for distinctiveness, irrespective of whether the Mark was distinctive for physicians and pharmacists. In addition, the Board was also wrong in law in not considering whether distinctiveness amongst patients was established "to any significant degree," and was unreasonable in failing to provide a sufficient evidentiary justification for finding distinctiveness amongst patients.

When the judge reviewed all of the relevant evidence it was found that Pfizer failed to establish that a substantial body of patients associated the blue, diamond-shaped unmarked Viagra pill with a single source. A similar conclusion was reached concerning physicians and pharmacists. As a result the appeal was dismissed.


This decision may assist those who wish to attempt to protect pharmaceutical tablets as it provides a roadmap, albeit lengthy. But the fact remains that it is very difficult to obtain protection.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

John McKeown
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.